Fig. 5. The lipid metabolic process was dysregulated by atractylodin. (A) Volcano plot depicting differential expression of genes in the atractylodin-treated group compared to the vehicle-treated group in HFD-fed mice. Genes with significant upregulation are shown in red, downregulated genes in blue, and genes with no significant difference in grey (│fold change│>1.5, p-value <0.05). (B) Top 10 Gene Ontology (GO) biological process (BP) analysis of major signaling pathways. Using the DAVID bioinformatics database. (C) Analysis of significantly enriched GO terms using the GO BP Direct database. (D) Heatmap illustrating the results of RNA-sequencing analysis for the lipid metabolic process (n=3). (E) Reduced hepatic mRNA expression of key enzyme involved in de novo lipogenesis, Srebf1 and Dgat2, in atractylodin-treated HFD-fed mice compared to vehicle-treated HFD-fed mice (n=8-9, each group). Data are presented as mean ± SEM. Statistical analysis was performed using one-way ANOVA with Tukey’s post-hoc test. **p<0.01: compared with ND+Veh; ##p<0.01: compared with HFD+Veh. (F) Representative Western blotting for fatty acid synthase (FAS).
© Biomolecules & Therapeutics
